Journal articles: 'Asthma in children – Treatment'

1

Rees, J., and J. Price. "ABC of Asthma: ASTHMA IN CHILDREN: TREATMENT." BMJ 310, no. 6993 (June 10, 1995): 1522–27. http://dx.doi.org/10.1136/bmj.310.6993.1522.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

&NA;. "Inappropriate asthma treatment in children." Inpharma Weekly &NA;, no. 894 (July 1993): 6. http://dx.doi.org/10.2165/00128413-199308940-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Speight, N. "Treatment of children with asthma." BMJ 311, no. 7008 (September 23, 1995): 810. http://dx.doi.org/10.1136/bmj.311.7008.810a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

van Aalderen, Wim M. "Childhood Asthma: Diagnosis and Treatment." Scientifica 2012 (2012): 1–18. http://dx.doi.org/10.6064/2012/674204.

Full text

Abstract:

Many children suffer from recurrent coughing, wheezing and chest tightness. In preschool children one third of all children have these symptoms before the age of six, but only 40% of these wheezing preschoolers will continue to have asthma. In older school-aged children the majority of the children have asthma. Quality of life is affected by asthma control. Sleep disruption and exercised induced airflow limitation have a negative impact on participation in sports and social activities, and may influence family life. The goal of asthma therapy is to achieve asthma control, but only a limited number of patients are able to reach total control. This may be due to an incorrect diagnosis, co-morbidities or poor inhalation technique, but in the majority of cases non-adherence is the main reason for therapy failures. However, partnership with the parents and the child is important in order to set individually chosen goals of therapy and may be of help to improve control. Non-pharmacological measures aim at avoiding tobacco smoke, and when a child is sensitised, to avoid allergens. In pharmacological management international guidelines such as the GINA guideline and the British Guideline on the Management of Asthma are leading.

APA, Harvard, Vancouver, ISO, and other styles

5

Papneja, Tripti, and Katharina Manassis. "Characterization and Treatment Response of Anxious Children with Asthma." Canadian Journal of Psychiatry 51, no. 6 (May 2006): 393–96. http://dx.doi.org/10.1177/070674370605100610.

Full text

Abstract:

Objectives: To compare children with Axis I anxiety disorders and asthma with a matched group of anxious children without asthma on questionnaire measures and response to cognitive-behavioural treatment (CBT) for anxiety. Method: A sample of 36 children with comorbid anxiety and asthma, aged 8 to 12 years, were matched for age, sex, and specific anxiety disorder with 36 children with an Axis I anxiety disorder but no asthma. Parents and children completed standardized questionnaires. Results: Children with comorbid anxiety and asthma had significantly more perinatal complications ( P = 0.001), and higher total ( P = 0.000) and psychological stressors ( P = 0.02), especially parent–child problems ( P = 0.01), but lower levels of depression ( P = 0.03) and anxiety ( P = 0.05), compared with anxious, nonasthmatic children. All children reported decreased anxiety ( P = 0.001) and depression ( P = 0.000) posttreatment, with a trend toward less improvement in anxiety in anxious children with asthma. Conclusions: Although replication is needed, addressing psychosocial stress and parent–child problems may increase CBT efficacy in children with comorbid anxiety and asthma.

APA, Harvard, Vancouver, ISO, and other styles

6

Porcaro, Federica, Nicola Ullmann, Annalisa Allegorico, Antonio Di Marco, and Renato Cutrera. "Difficult and Severe Asthma in Children." Children 7, no. 12 (December 10, 2020): 286. http://dx.doi.org/10.3390/children7120286.

Full text

Abstract:

Asthma is the most frequent chronic inflammatory disease of the lower airways affecting children, and it can still be considered a challenge for pediatricians. Although most asthmatic patients are symptom-free with standard treatments, a small percentage of them suffer from uncontrolled persistent asthma. In these children, a multidisciplinary systematic assessment, including comorbidities, treatment-related issues, environmental exposures, and psychosocial factors is needed. The identification of modifiable factors is important to differentiate children with difficult asthma from those with true severe therapy-resistant asthma. Early intervention on modifiable factors for children with difficult asthma allows for better control of asthma without the need for invasive investigation and further escalation of treatment. Otherwise, addressing a correct diagnosis of true severe therapy-resistant asthma avoids diagnostic and therapeutic delays, allowing patients to benefit from using new and advanced biological therapies.

APA, Harvard, Vancouver, ISO, and other styles

7

Carlsen, Kai-Hakon. "Pharmaceutical Treatment of Asthma in Children." Current Drug Target -Inflammation & Allergy 4, no. 5 (October 1, 2005): 543–49. http://dx.doi.org/10.2174/156801005774322216.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Solé, Dirceu, Inês Camelo-Nunes, Maria Cândida Rizzo, and Charles K. Naspitz. "Asthma in children: classification and treatment." Jornal de Pediatria 74, no. 7 (November 15, 1998): 48–58. http://dx.doi.org/10.2223/jped.486.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Bierman, C. Warren, David S. Pearlman, William E. Pierson, Gail G. Shapiro, and Clifton T. Furukawa. "Treatment of Acute Asthma in Children." Pediatrics International 29, no. 6 (December 1987): 793–99. http://dx.doi.org/10.1111/j.1442-200x.1987.tb00382.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Lu, Min, Beirong Wu, Datian Che, Rong Qiao, and Haoxiang Gu. "FeNO and Asthma Treatment in Children." Medicine 94, no. 4 (January 2015): e347. http://dx.doi.org/10.1097/md.0000000000000347.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Volovitz, B. "Treatment of severe asthma in children." Biomedicine & Pharmacotherapy 49, no. 4 (January 1995): 219. http://dx.doi.org/10.1016/0753-3322(96)82625-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Devonshire, Ashley L., and Rajesh Kumar. "Pediatric asthma: Principles and treatment." Allergy and Asthma Proceedings 40, no. 6 (November 1, 2019): 389–92. http://dx.doi.org/10.2500/aap.2019.40.4254.

Full text

Abstract:

Approximately one-half of children with asthma present with symptoms before 3 years of age. The typical history describes recurrent episodes of wheezing and/or cough triggered by a viral upper respiratory infection (URI), activity, or changes in weather. When symptoms occur after a viral URI, children with asthma often take longer than the usual week to fully recover from their respiratory symptoms. Wheezing and coughing during exercise or during laughing or crying, and episodes triggered in the absence of infection suggest asthma. A trial of bronchodilator medication should show symptomatic improvement. The goal of asthma therapy is to keep children “symptom free” by preventing chronic symptoms, maintaining lung function, and allowing for normal daily activities. Avoidance of triggers identified by a history, such as second-hand cigarette smoke exposure, and allergens identified by skin-prick testing can significantly reduce symptoms. According to the 2007 National Asthma Education and Prevention Program (NAEPP) report, if impairment symptoms are present for >2 days/week or 2 nights/month, then the disease process is characterized as persistent, and, in all age groups, inhaled corticosteroids (ICS) are recommended as the preferred daily controller therapy. Montelukast is approved for children ages ≥ 12 months and is often used for its ease of daily oral dosing. Long-acting beta-2 adrenergic agonists should only be used in combination with an ICS. For more-severe or difficult-to-control phenotypes, biologic therapy has been developed, which targets the type of inflammation present.

APA, Harvard, Vancouver, ISO, and other styles

13

Sicouri, Gemma, Louise Sharpe, Jennifer L. Hudson, Joanne Dudeney, Adam Jaffe, and Caroline Hunt. "A Case Series Evaluation of a Pilot Group Cognitive Behavioural Treatment for Children With Asthma and Anxiety." Behaviour Change 34, no. 1 (March 16, 2017): 35–47. http://dx.doi.org/10.1017/bec.2017.3.

Full text

Abstract:

Anxiety disorders occur at an increased rate in children with asthma; however, there is only a small evidence base to support specific psychological treatments for these children. The current study evaluated the efficacy of a pilot cognitive behavioural treatment (CBT) group intervention for children with asthma and a comorbid anxiety disorder in a case series design. Five children (aged 8–11 years old) with asthma and a comorbid anxiety disorder and their mothers took part in eight 1-hour group treatment sessions. Primary outcomes measures were anxiety diagnosis and asthma-related quality of life. Secondary outcome measures were asthma symptom control and parent quality of life associated with caring for a child with asthma. Three of the participants no longer met diagnostic criteria for an anxiety disorder following treatment and three different participants reported a reliable improvement in asthma-related quality of life. Two participants reported a reliable improvement in asthma symptom control. Three mothers reported an improvement in caregiver quality of life. The findings provide preliminary proof of concept evidence for the efficacy of a CBT intervention for children with asthma and clinical anxiety.

APA, Harvard, Vancouver, ISO, and other styles

14

Pike, Katharine C., Mark L. Levy, John Moreiras, and Louise Fleming. "Managing problematic severe asthma: beyond the guidelines." Archives of Disease in Childhood 103, no. 4 (September 13, 2017): 392–97. http://dx.doi.org/10.1136/archdischild-2016-311368.

Full text

Abstract:

This review discusses issues related to managing problematic severe asthma in children and young people. A small minority of children have genuinely severe asthma symptoms which are difficult to control. Children with genuinely severe asthma need investigations and treatments beyond those described within conventional guidelines. However, the majority of children with poor symptom control despite high-intensity treatment achieve improvement in their asthma control once attention has been paid to the basics of asthma management. Basic asthma management requires optimisation of inhaler technique and treatment adherence, avoidance of environmental triggers and self-management education. It is also important that clinicians recognise risk factors that predispose patients to asthma exacerbations and potentially life-threatening attacks. These correctable issues need to be tackled in partnership with children and young people and their families. This requires a coordinated approach between professionals across healthcare settings. Establishing appropriate infrastructure for coordinated asthma care benefits not only those with problematic severe asthma, but also the wider asthma population as similar correctable issues exist for children with asthma of all severities. Investigation and management of genuine severe asthma requires specialist multidisciplinary expertise and a systematic approach to characterising patients’ asthma phenotypes and delivering individualised care. While inhaled corticosteroids continue to play a leading role in asthma therapy, new treatments on the horizon might further support phenotype-specific therapy.

APA, Harvard, Vancouver, ISO, and other styles

15

Lovrić, Mario, Ivana Banić, Emanuel Lacić, Kristina Pavlović, Roman Kern, and Mirjana Turkalj. "Predicting Treatment Outcomes Using Explainable Machine Learning in Children with Asthma." Children 8, no. 5 (May 10, 2021): 376. http://dx.doi.org/10.3390/children8050376.

Full text

Abstract:

Asthma in children is a heterogeneous disease manifested by various phenotypes and endotypes. The level of disease control, as well as the effectiveness of anti-inflammatory treatment, is variable and inadequate in a significant portion of patients. By applying machine learning algorithms, we aimed to predict the treatment success in a pediatric asthma cohort and to identify the key variables for understanding the underlying mechanisms. We predicted the treatment outcomes in children with mild to severe asthma (N = 365), according to changes in asthma control, lung function (FEV1 and MEF50) and FENO values after 6 months of controller medication use, using Random Forest and AdaBoost classifiers. The highest prediction power is achieved for control- and, to a lower extent, for FENO-related treatment outcomes, especially in younger children. The most predictive variables for asthma control are related to asthma severity and the total IgE, which were also predictive for FENO-based outcomes. MEF50-related treatment outcomes were better predicted than the FEV1-based response, and one of the best predictive variables for this response was hsCRP, emphasizing the involvement of the distal airways in childhood asthma. Our results suggest that asthma control- and FENO-based outcomes can be more accurately predicted using machine learning than the outcomes according to FEV1 and MEF50. This supports the symptom control-based asthma management approach and its complementary FENO-guided tool in children. T2-high asthma seemed to respond best to the anti-inflammatory treatment. The results of this study in predicting the treatment success will help to enable treatment optimization and to implement the concept of precision medicine in pediatric asthma treatment.

APA, Harvard, Vancouver, ISO, and other styles

16

Pijnenburg, Mariëlle W., Eugenio Baraldi, Paul L. P. Brand, Kai-Håkon Carlsen, Ernst Eber, Thomas Frischer, Gunilla Hedlin, et al. "Monitoring asthma in children." European Respiratory Journal 45, no. 4 (March 5, 2015): 906–25. http://dx.doi.org/10.1183/09031936.00088814.

Full text

Abstract:

The goal of asthma treatment is to obtain clinical control and reduce future risks to the patient. To reach this goal in children with asthma, ongoing monitoring is essential. While all components of asthma, such as symptoms, lung function, bronchial hyperresponsiveness and inflammation, may exist in various combinations in different individuals, to date there is limited evidence on how to integrate these for optimal monitoring of children with asthma. The aims of this ERS Task Force were to describe the current practise and give an overview of the best available evidence on how to monitor children with asthma.22 clinical and research experts reviewed the literature. A modified Delphi method and four Task Force meetings were used to reach a consensus.This statement summarises the literature on monitoring children with asthma. Available tools for monitoring children with asthma, such as clinical tools, lung function, bronchial responsiveness and inflammatory markers, are described as are the ways in which they may be used in children with asthma. Management-related issues, comorbidities and environmental factors are summarised.Despite considerable interest in monitoring asthma in children, for many aspects of monitoring asthma in children there is a substantial lack of evidence.

APA, Harvard, Vancouver, ISO, and other styles

17

Masekela, R., A. Jeevanathrum, S. Kling, T. C. Gray, J. Morrison, A. Vanker, A. S. Puterman, et al. "Asthma treatment in children: A pragmatic approach." South African Medical Journal 108, no. 8 (July 25, 2018): 612. http://dx.doi.org/10.7196/samj.2018.v108i8.13164.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Brand, Paul LP. "Treatment of mild persistent asthma in children." Lancet 377, no. 9779 (May 2011): 1743. http://dx.doi.org/10.1016/s0140-6736(11)60723-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Levy, Mark L. "Treatment of mild persistent asthma in children." Lancet 377, no. 9779 (May 2011): 1743. http://dx.doi.org/10.1016/s0140-6736(11)60724-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Panontin, Elisa, and Giorgio Longo. "Treatment of mild persistent asthma in children." Lancet 377, no. 9779 (May 2011): 1743–44. http://dx.doi.org/10.1016/s0140-6736(11)60725-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Hesselmar, Bill, Nils Åberg, Birgitta Åberg, and Bo Eriksson. "Asthma in children: Prevalence, treatment, and sensitization." Pediatric Allergy and Immunology 11, no. 2 (May 2000): 74–79. http://dx.doi.org/10.1034/j.1399-3038.2000.00070.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Kelly, H. William, and Shirley Murphy. "Helping Children Adhere to Asthma Treatment Regimens." Pediatric Asthma, Allergy & Immunology 15, no. 1 (March 2001): 25–30. http://dx.doi.org/10.1089/088318701750314545.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Szefler, Stanley J. "Current concepts in asthma treatment in children." Current Opinion in Pediatrics 16, no. 3 (June 2004): 299–304. http://dx.doi.org/10.1097/01.mop.0000125069.73952.a4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Redwood, Tracey, and Sarah Neill. "Diagnosis and treatment of asthma in children." Practice Nursing 24, no. 5 (May 2013): 222–29. http://dx.doi.org/10.12968/pnur.2013.24.5.222.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Van Asperen, P. P. "The drug treatment of asthma in children." Indian Journal of Pediatrics 54, no. 5 (September 1987): 665–72. http://dx.doi.org/10.1007/bf02751274.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Booster, Genery D., Alyssa A. Oland, and Bruce G. Bender. "Treatment Adherence in Young Children with Asthma." Immunology and Allergy Clinics of North America 39, no. 2 (May 2019): 233–42. http://dx.doi.org/10.1016/j.iac.2018.12.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Schultz, André, and Andrew C. Martin. "Outpatient Management of Asthma in Children." Clinical Medicine Insights: Pediatrics 7 (January 2013): CMPed.S7867. http://dx.doi.org/10.4137/cmped.s7867.

Full text

Abstract:

The principal aims of asthma management in childhood are to obtain symptom control that allows individuals to engage in unrestricted physical activities and to normalize lung function. These aims should be achieved using the fewest possible medications. Ensuring a correct diagnosis is the first priority. The mainstay of asthma management remains pharmacotherapy. Various treatment options are discussed. Asthma monitoring includes the regular assessment of asthma severity and asthma control, which then informs decisions regarding the stepping up or stepping down of therapy. Delivery systems and devices for inhaled therapy are discussed, as are the factors influencing adherence to prescribed treatment. The role of the pediatric health care provider is to establish a functional partnership with the child and their family in order to minimize the impact of asthma symptoms and exacerbations during childhood.

APA, Harvard, Vancouver, ISO, and other styles

28

Irfan, Sumaira, Zahid Mahmood Anjum, Ali Asgher Taseer, and Hina Ayesha. "ACUTE SEVERE ASTHMA IN CHILDREN." Professional Medical Journal 22, no. 08 (August 10, 2015): 1039–43. http://dx.doi.org/10.29309/tpmj/2015.22.08.1152.

Full text

Abstract:

Objective: To compare the efficacy of intravenous magnesium sulfate andconventional treatment with conventional treatment alone in acute severe asthma in children ofage group 5 to 15 years known cases of bronchial asthma. Study design: Randomized controltrial. Setting: Indoor and outdoor patients of pediatrics department of DHQ hospital, Faisalabad.Duration: Six months. Results: In this study, 43.58%(n=17) in Exposed and 53.85%(n=21) inUn-exposed group were male and remaining 56.42%(n=22) and 46.15%(n=18) were females,mean pulse rate in both groups was recorded which shows 97.32+6.58 in Exposed Groupand 103.67+8.32 in Un-exposed Group, p value was calculated as 0.02, mean FEV1 rate inboth groups was recorded which shows 60.32+7.56 in Exposed Group and 54.07+6.43 in UnexposedGroup, p value was calculated as 0.03. Conclusion: We concluded that intravenousmagnesium sulfate along with conventional treatment is significantly better than conventionaltreatment alone for the management of acute severe asthma attack.

APA, Harvard, Vancouver, ISO, and other styles

29

Rachelefsky, Gary S., and Sheldon C. Siegel. "Asthma in infants and children—Treatment of childhood asthma: Part II." Journal of Allergy and Clinical Immunology 76, no. 3 (September 1985): 409–25. http://dx.doi.org/10.1016/0091-6749(85)90718-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Glushkova, Evgeniya F., and Tatiana N. Surovenko. "Is it always easy for children with mild asthma?" Meditsinskiy sovet = Medical Council, no. 1 (March 21, 2021): 203–12. http://dx.doi.org/10.21518/2079-701x-2021-1-203-212.

Full text

Abstract:

Bronchial asthma is the most common chronic disease of children, the worst way is their quality of life. Compliance in the treatment of children is very important, since the actual effect of a drug is determined by both the effective drugs and patient adherence and correct use. A relevant test is the use of mild asthma, which is able to control bronchial hyperreactivity associated with exercise, cold air, and other nonspecific irritants (smoke, odors, etc.). Planning of baseline therapy for children with mild asthma aged 5 years old and younger is particularly problematic for paediatricians due to high incidences of acute respiratory viral diseases and viral-induced exacerbations of bronchial asthma among them. In these children, allergen-specific immunotherapy, long-acting B-agonists, the use of many metered-dose inhaled glucocorticosteroids. are not recommended.Montelukast, an oral antileukotriene drug, has advantages in the treatment of children with mild asthma with virus-induced exacerbations, with asthma of physical exertion and severe bronchial hyperreactivity, especially when combined with allergic rhinitis, as well as in special clinical cases, when parents refuse to use ICS for treatment children with mild asthma or inability to use them for some reason. The use of montelukast for mild asthma in children in the current context of the COVID-19 pandemic also has advantages that pediatricians can use when observing these children in the pediatric area, taking into account contraindications.

APA, Harvard, Vancouver, ISO, and other styles

31

Sancakli, Ozlem, and Asli Akin Aslan. "The effects of maternal anxiety and attitudes on the adherence to inhaled corticosteroids in children with asthma." Allergologia et Immunopathologia 49, no. 3 (May 1, 2021): 138–45. http://dx.doi.org/10.15586/aei.v49i3.196.

Full text

Abstract:

Objective: Long-term inhaled corticosteroid (ICS) use in children with asthma causes serious concerns in parents, leading to treatment non-adherence. This study aimed to investigate the effect of maternal anxiety and attitudes on adherence to ICS therapy in children with asthma. Method: The patient group included the children with mild to moderate persistent asthma, aged 6–11 years. Healthy children in a similar age range were included as a control group. The patient group was divided into two categories (treatment adherent and non-adherent) accord-ing to the regularity of ICS use. All patients were assessed with Childhood-Asthma Control Test (C-ACT), and their mothers were assessed using Parent Attitude Research Instrument (PARI) and Beck’s Anxiety Inventory (BAI).Results: A total of 156 children (age: 7.4 ± 1.4 years, F/M: 71/85) with persistent asthma and 60 healthy children (age: 7.5 ± 1.3 years, F/M:25/35) were included in the study. The rate of adher-ence in children with asthma was 52.6%. Mothers of non-adherent patients had significantly higher BAI scores than those of the adherent patients and controls (p < 0.001 and p < 0.001, respectively). The number of mothers who indicated that they did not have enough informa-tion about asthma and treatment was also higher in the non-adherent group. PARI subtest scores were not different between the adherent and non-adherent groups.Conclusions: In our study, it was found that mothers’ anxiety levels and their knowledge about asthma and medications were associated with treatment adherence in children with asthma. Psychological and educational support to the families of children with asthma would improve their treatment adherence and efficacy.

APA, Harvard, Vancouver, ISO, and other styles

32

Petersen, R. "Treatment of exercise-induced asthma with beclomethasone dipropionate in children with asthma." European Respiratory Journal 24, no. 6 (December 1, 2004): 932–37. http://dx.doi.org/10.1183/09031936.04.00141303.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Adams, Sue K., Karla Klein Murdock, Elizabeth L. McQuaid, and Lori-Ann Lima. "The Role of Parents' Medication Beliefs, Religious Problem-Solving, and Risks for Treatment Nonadherence in Urban Families with Asthma." Health Services Insights 4 (January 2011): HSI.S6464. http://dx.doi.org/10.4137/hsi.s6464.

Full text

Abstract:

Childhood asthma is highly prevalent, affecting approximately nine million children in the United States. Negative effects of pediatric asthma are disproportionately experienced by ethnic minorities living in low-income, urban settings. Given the great diversity in families' ways of addressing children's asthma symptoms, sociocultural factors underlying asthma disparities must be examined. The current study investigated associations among parents' beliefs about conventional and holistic/alternative medications, parents' religious problem-solving strategies and childrens' risks for asthma treatment nonadherence. The sample included 66 parents of ethnically diverse children with asthma living in urban settings. Factor analysis of the Religious Problem Solving Questionnaire yielded two factors, self-directed (ie, solving problems independently of God) and God-involved problem solving. Parents' strong positive beliefs about conventional and alternative medications were associated with greater self-directed problem solving and with more risks for nonadherence. Higher levels of self-directed problem solving also were associated with more risks for nonadherence. Self-directed problem solving mediated the associations of conventional and alternative medication beliefs with risks for nonadherence. Possible explanations for these findings are discussed.

APA, Harvard, Vancouver, ISO, and other styles

34

Payne, Donald, and Andrew Bush. "Phenotype-specific treatment of difficult asthma in children." Paediatric Respiratory Reviews 5, no. 2 (June 2004): 116–23. http://dx.doi.org/10.1016/j.prrv.2004.01.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Friday, Gilbert A., Hnin Khine, Ming S. Lin, and Lawrence A. Caliguiri. "Profile of Children Requiring Emergency Treatment for Asthma." Annals of Allergy, Asthma & Immunology 78, no. 2 (February 1997): 221–24. http://dx.doi.org/10.1016/s1081-1206(10)63391-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Iwona, Stelmach, and Grzelewski Tomasz. "Antileukotriene Treatment in Children with Asthma - New Patents." Recent Patents on Inflammation & Allergy Drug Discovery 2, no. 3 (November 1, 2008): 202–11. http://dx.doi.org/10.2174/187221308786241938.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Chipps, Bradley E., and Kevin R. Murphy. "Assessment and Treatment of Acute Asthma in Children." Journal of Pediatrics 147, no. 3 (September 2005): 288–94. http://dx.doi.org/10.1016/j.jpeds.2005.04.052.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Chambers, C. "Step-up treatment for children with uncontrolled asthma." Thorax 65, no. 12 (October 29, 2010): 1106. http://dx.doi.org/10.1136/thx.2010.145573.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Ricciardolo, Fabio L. M. "The treatment of asthma in children: Inhaled corticosteroids." Pulmonary Pharmacology & Therapeutics 20, no. 5 (October 2007): 473–82. http://dx.doi.org/10.1016/j.pupt.2005.11.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Harrington, N., N. Prado, and S. Barry. "Dental treatment in children with asthma – a review." British Dental Journal 220, no. 6 (March 2016): 299–302. http://dx.doi.org/10.1038/sj.bdj.2016.220.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Ross, A. M., and D. M. Fleming. "Review of prescribed treatment for children with asthma." BMJ 311, no. 7020 (December 16, 1995): 1644–45. http://dx.doi.org/10.1136/bmj.311.7020.1644c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Sherwood Brown, E., Vanthaya Gan, Jala Jeffress, Beatrice L. Wood, Bruce D. Miller, and David A. Khan. "Antidepressant Treatment of Caregivers of Children With Asthma." Psychosomatics 49, no. 5 (September 2008): 420–25. http://dx.doi.org/10.1176/appi.psy.49.5.420.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Celano, Marianne, Robert j. Geller, Keith M. Phillips, and Robin Ziman. "Treatment Adherence Among Low-Income Children With Asthma." Journal of Pediatric Psychology 23, no. 6 (1998): 345–49. http://dx.doi.org/10.1093/jpepsy/23.6.345.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Kerrebijn, K. F. "Long-term drug treatment of asthma in children." Lung 168, S1 (December 1990): 142–53. http://dx.doi.org/10.1007/bf02718127.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Eizayaga, Francisco Xavier, Francisco Xavier Eizayaga, and Jose Eizayaga. "Homoeopathic treatment of bronchial asthma." British Homeopathic Journal 85, no. 01 (January 1996): 28–33. http://dx.doi.org/10.1016/s0007-0785(96)80022-6.

Full text

Abstract:

AbstractA retrospective evaluation of the results of the homoeopathic treatment of 62 patients suffering from bronchial asthma showed a very significant statistical improvement in the condition. Strict inclusion and exclusion criteria were applied after a random trawl of cases from our files. The results were evaluated in terms of the general population and according to age at start of treatment, to take account of the high incidence of spontaneous remission in children. The clinical approach of the homoeopath is discussed, with reference to the prescribing of medicines.

APA, Harvard, Vancouver, ISO, and other styles

46

Licari, Amelia, Riccardo Castagnoli, Enrico Tondina, Giorgia Testa, Giuseppe Fabio Parisi, Alessia Marseglia, Ilaria Brambilla, and Gian Luigi Marseglia. "Novel Biologics for the Treatment of Pediatric Severe Asthma." Current Respiratory Medicine Reviews 15, no. 3 (January 1, 2020): 195–204. http://dx.doi.org/10.2174/1573398x15666190521111816.

Full text

Abstract:

Estimated to represent less than 5% of all asthmatic patients, children with severe asthma experience troublesome persistent symptoms, life-threatening attacks and side effects by oral corticosteroid treatment, that significantly impact on the quality of life and on economic costs. An accurate understanding of the mechanisms of the disease has been crucial for the discovery and development of biological therapies, for which children with severe asthma are candidates. The aim of this review is to discuss the use of approved biologics for severe asthma, providing updated evidence of novel targeted therapies in the pediatric age range.

APA, Harvard, Vancouver, ISO, and other styles

47

Lapierre, Guy. "Beta2-Agonists and Asthma in Children." Canadian Respiratory Journal 2, suppl a (1995): 35A—37A. http://dx.doi.org/10.1155/1995/697362.

Full text

Abstract:

Due to the growing prevalence and morbidity of asthma in children in the past few years, Canadian physicians have addressed several issues concerning the correct use of beta2-agonists for the treatment of asthma. These issues include the optimum delivery systems for beta2-agonists, their appropriate dosages in children, infants and toddlers, and whether tachyphylaxis occurs with their chronic use.

APA, Harvard, Vancouver, ISO, and other styles

48

Surovenko, T. N., and Е. F. Glushkova. "New possibilities for asthma therapy in children." Medical Council, no. 17 (October 22, 2018): 192–98. http://dx.doi.org/10.21518/2079-701x-2018-17-192-198.

Full text

Abstract:

This article discusses issues of clinical diagnosis and course of bronchial asthma in children. We discuss assessment of asthma severity and, accordingly, the extent of the step-by-step therapy according to updated recommendations (GINA 2018). Particular attention is paid to the possibility of improving the control of asthma with the help of the M-cholinolytic drug of long-acting tiotropium bromide, presented as a special inhalation form of tiotropium Respimat and registered in the Russian Federation for treatment of asthma in children of moderate and severe course from 6 years of age. Application tiotropium Respimat in children with insufficient control of asthma allows to improve lung function and asthma control.

APA, Harvard, Vancouver, ISO, and other styles

49

Perez-Garcia, Javier, Esther Herrera-Luis, Fabian Lorenzo-Diaz, Mario González, Olaia Sardón, Jesús Villar, and Maria Pino-Yanes. "Precision Medicine in Childhood Asthma: Omic Studies of Treatment Response." International Journal of Molecular Sciences 21, no. 8 (April 21, 2020): 2908. http://dx.doi.org/10.3390/ijms21082908.

Full text

Abstract:

Asthma is a heterogeneous and multifactorial respiratory disease with an important impact on childhood. Difficult-to-treat asthma is not uncommon among children, and it causes a high burden to the patient, caregivers, and society. This review aims to summarize the recent findings on pediatric asthma treatment response revealed by different omic approaches conducted in 2018–2019. A total of 13 studies were performed during this period to assess the role of genomics, epigenomics, transcriptomics, metabolomics, and the microbiome in the response to short-acting beta agonists, inhaled corticosteroids, and leukotriene receptor antagonists. These studies have identified novel associations of genetic markers, epigenetic modifications, metabolites, bacteria, and molecular mechanisms involved in asthma treatment response. This knowledge will allow us establishing molecular biomarkers that could be integrated with clinical information to improve the management of children with asthma.

APA, Harvard, Vancouver, ISO, and other styles

50

Yakovleva, M. G., V. N. Seroklinov, A. V. Suvorova, A. A. Chursin, T. A. Tokareva, T. V. Logvinova, and N. V. Ulchenko. "New abilities of therapy of asthma in outpatient children." PULMONOLOGIYA, no. 5 (October 28, 2007): 58–62. http://dx.doi.org/10.18093/0869-0189-2007-0-5-58-62.

Full text

Abstract:

Effective, safe and convenient inhalation therapy of asthma is of particular importance in pediatric practice. We performed open randomized comparative trial to evaluate efficacy of ultra-fine Beclazone ECO Ease Breathe (BEEB) vs fluticasone in equal doses in children with asthma. The study involved 40 children (26 males, 14 females) of 6-17 years of age with moderate asthma. They were treated with fluticasone followed by BEEB 250 μg b.i.d. We analyzed clinical findings, frequency and severity of asthma symptoms, peak expiratory flow rate (PEFR), medications used for asthma, lung function parameters. After 2 months of treatment with BEEB, the full control of asthma has been achieved in 11 patients (27.5 %) vs 9 patients treated with fluticasone (22.5 %). The good control was achieved in 27 (67.5 %) and 28 (70 %) patients, respectively. The asthma control was poor in 2 patients with BEEB (5 %) and 3 patients with fluticasone (7.5 %). Moderate improvement in mean FEV 1 and PEFR and reduction of their postbronchodilator growth were noted. All the children easily acquired the proper inhalation technique for BEEB. After 2 months of treatment, 39 of 40 patients have wished to continue therapy with this inhaler. There were no adverse events of the drug. There were no additional expenses for asthma and need of hospitalization or other medical care during the study. Therefore, BEEB as the basic therapy of childhood moderate asthma improves asthma control and compliance of the patient and the physician, and significantly decreases the cost of treatment.

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Asthma in children – Treatment'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles